This move is archived. Current quotes and coverage live on the stock page.
Follow HBP
Helix BioPharma Corp. is seeing a noticeable increase in its stock price, which shows a rise in investor confidence.
Helix BioPharma Corp. (HBP.TO) is up today, gaining 2.94% to close at CA$1.75. This rise suggests positive sentiment among investors, likely driven by recent company developments and strategic initiatives.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$69.50M
52W high
$5.40
52W low
$0.91
1W change
-17.27%
Beta
-0.27
Analyst Price Targets
Based on analyst covering HBP · as of Sep 17, 2026
Wall Street analysts forecast HBP stock price to rise 174.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+174.7% Upside
Current Price
C$0.91
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
106.1%
Annualized
90-Day Vol
75.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.76
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.86 | C$0.59 – C$1.24 |
| 60 trading days | C$0.81 | C$0.48 – C$1.36 |
| 90 trading days | C$0.76 | C$0.40 – C$1.44 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider the potential of Helix BioPharma's oncology programs as a key factor for future growth, especially given its recent efforts to raise capital.
CA$1.75
Helix BioPharma's market capitalization is CA$126.79 million, highlighting its position in the biotech sector.
Bull case
The company is focused on advancing its oncology programs and has recently secured funding agreements, which could give it a competitive edge and attract institutional interest.
Bear case
Even with today’s gains, Helix BioPharma faces challenges in a tough capital markets environment, which might affect its ability to carry out its strategic plans effectively.
Recent Developments
Advertisement
Helix BioPharma has been proactive in securing funding to advance its oncology programs. The recent capital raising agreement with Kerentech Consulting Ltd. is a significant step toward closing a USD 13 million bridge financing round, which could strengthen its operational capabilities.
Market Response
The stock's rise today reflects a positive market reaction to Helix BioPharma's efforts to stabilize its financial position and improve its growth prospects. Investors seem optimistic about the company's future, particularly with its focus on therapeutic advancements.
Looking Ahead
As Helix BioPharma navigates the complexities of the biotech landscape, its ability to attract investments and successfully implement its strategic initiatives will be crucial. The market will be watching closely to see how these factors unfold in the coming months.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
